Research ArticleCancer

Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy

See allHide authors and affiliations

Science Translational Medicine  20 Mar 2019:
Vol. 11, Issue 484, eaar5012
DOI: 10.1126/scitranslmed.aar5012

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

A mini-protein with mighty effects

The transcription factor MYC is an oncogene that has been implicated in a variety of cancers but has proven very difficult to target therapeutically. Omomyc mini-protein is a dominant-negative form of MYC that is used to inhibit MYC for research purposes but was thought to be too unwieldy for in vivo therapy. However, Beaulieu et al. discovered that Omomyc can penetrate into cancer cells in vitro and in vivo. The authors used mouse models of non–small cell lung cancer to demonstrate the effectiveness of Omomyc delivered intranasally or intravenously, alone or combined with chemotherapy, setting the stage for potential clinical development of this mini-protein.

View Full Text